Axial Biotherapeutics

OverviewSuggest Edit

Axial Biotherapeutics is the latest microbiome firm to emerge. Private and venture capital investors, including Longwood Fund and Domain Associates, have put an initial $19 million into the California start-up.

Axial is based on the work of California Institute of Technology professor Sarkis Mazmanian. In mouse models, his lab has shown a connection between neurological disorders and interventions in the gut microbiome. Axial intends to expand on these discoveries to find pathways and mechanisms amenable to biotherapeutic intervention. Initial disease targets include autism and Parkinson’s disease.

Technology that Axial has licensed from Caltech includes Mazmanian’s work involving Bacteroides fragiles. Raising the level of these gut bacteria can reduce autism-like behavior in engineered mice.

HQWaltham, US

Latest Updates

Cybersecurity ratingDMore

Key People/Management at Axial Biotherapeutics

Eric de la Fortelle

Eric de la Fortelle

Scott C. Brun

Scott C. Brun

Sakae Asanuma

Sakae Asanuma

Jim Blair

Jim Blair

Jeffrey Young

Jeffrey Young

Chief Financial Officer
A. Stewart Campbell

A. Stewart Campbell

Senior Vice President, Research & Development
Show more

Axial Biotherapeutics Office Locations

Axial Biotherapeutics has an office in Waltham
Waltham, US (HQ)
9 4th Ave
Show all (1)

Axial Biotherapeutics Financials and Metrics

Summary Metrics

Founding Date


Axial Biotherapeutics total Funding

$54.5 m

Axial Biotherapeutics latest funding size

$10 m

Time since last funding

a year ago

Axial Biotherapeutics investors

Axial Biotherapeutics's latest funding round in June 2019 was reported to be $10 m. In total, Axial Biotherapeutics has raised $54.5 m
Show all financial metrics

Axial Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Axial Biotherapeutics Online and Social Media Presence

Embed Graph

Axial Biotherapeutics Blogs

Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease Therapeutics

WALTHAM, Mass., July 28, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Found…
Show more

Axial Biotherapeutics Frequently Asked Questions

  • When was Axial Biotherapeutics founded?

    Axial Biotherapeutics was founded in 2013.

  • Who are Axial Biotherapeutics key executives?

    Axial Biotherapeutics's key executives are Eric de la Fortelle, Scott C. Brun and Sakae Asanuma.

  • Who are Axial Biotherapeutics competitors?

    Competitors of Axial Biotherapeutics include Principia BioPharma, Vectura Group and Chiasma.

  • Where is Axial Biotherapeutics headquarters?

    Axial Biotherapeutics headquarters is located at 9 4th Ave, Waltham.

  • Where are Axial Biotherapeutics offices?

    Axial Biotherapeutics has an office in Waltham.

  • How many offices does Axial Biotherapeutics have?

    Axial Biotherapeutics has 1 office.